Veteran Oncologist and Clinical Development expert to lead global medical strategy supporting patient-focused drug development and delivery Veteran Oncologist and Clinical Development expert to lead global medical strategy supporting patient-focused drug development and delivery
Read more from the original source:
Parexel appoints Charlotte Moser, MD, PhD, MBA as Chief Medical Officer
SOUTH SAN FRANCISCO, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to LYL314 (formerly IMPT-314) for the treatment of adult patients with relapsed and/or refractory large B-cell lymphoma after two or more prior lines of therapy. LYL314 is a next-generation dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to the approved CD19?targeted CAR T-cell therapies for the treatment of aggressive large B-cell lymphoma (LBCL).
SOUTH SAN FRANCISCO, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced participation in the following December investor events.
See the rest here:
Pliant Therapeutics to Participate in Upcoming Investor Events
MORRISVILLE, N.C., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, was a key enrolling site for the primary completion of a Phase 3 rare disease trial sponsored by global biopharmaceutical company, GSK. The hepatology study of an investigational medicine for cholestatic pruritus in primary biliary cholangitis (PBC) required 230 global participants, of which Science 37 was able to contribute almost half (17 - 47%) of the U.S. enrollment for the study.
Originally posted here:
Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease Trial
The Company's class A ordinary shares will begin trading on a split-adjusted basis on November 25, 2024 The Company's class A ordinary shares will begin trading on a split-adjusted basis on November 25, 2024
Read the original:
Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split
– In two studies the acellular tissue engineered vessel (ATEV) provided benefits in terms of patency, limb salvage, and infection resistance compared to current synthetic graft treatment benchmarks –
Read this article:
Humacyte Clinical Results Highlighting Benefit of the ATEV™ in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery
REHOVOT, Israel and WASHINGTON, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Biolojic Design, a biotechnology company that uses computational biology and artificial intelligence (AI) to transform antibodies into programmable, intelligent medicines, today announced the appointment of Neal Curran as Chief Business Officer. Mr. Curran joins Biolojic Design with extensive experience in business development in the biopharmaceutical industry and comes to the company as it expands its business and development activities in the U.S.
Read the rest here:
Biolojic Design Appoints Neal Curran as Chief Business Officer
SEATTLE, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Redhook Ale Brewery (“Redhook”), Seattle’s pioneering craft brewery and a subsidiary of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), officially presents their new partnership with the Montlake Futures NIL Collective, supporting student-athletes at the University of Washington (UW). Together, they launched Montlake Gameday Gold Lager, the Official Beer of the Montlake Futures NIL Collective. This unique lager stands out as the only beer dedicated to supporting UW student athletes.
LJUBLJANA, Slovenia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Protein Evolution, a pioneer in enzyme-driven plastics recycling, has announced a collaboration with Acies Bio, an innovative biotechnology company specializing in microbial R&D and biomanufacturing. This partnership aims to leverage Acies Bio’s state-of-the-art SmartRoute™ platform to scale the production of Protein Evolution’s plastic-degrading enzymes, bringing the world one step closer to a future free from plastic waste.
Read the original post:
Acies Bio and Protein Evolution Announce Strategic Partnership to Advance Biological Recycling Technology
Presentations include first reporting of data for the RESET™ Clinical Trial evaluating SPRINT PNS versus Standard Interventional Management for low back pain Presentations include first reporting of data for the RESET™ Clinical Trial evaluating SPRINT PNS versus Standard Interventional Management for low back pain